Policy & Regulation
Teva reports positive Phase 2a data for TEV '408 in celiac disease
2 September 2026 - Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on Wednesday reported positive top-line results from an ongoing Phase 2a study of TEV &...
Ono Pharma partners with Aitia on neurological disease drug discovery
2 September 2026 - Japanese pharmaceutical company Ono Pharmaceutical Co Ltd (TYO:4528) said on Wednesday that it has entered into a drug discovery partnership with US biotechnology company Aitia Inc ...
BioMarin completes Alesta Therapeutics acquisition
2 September 2026 - Rare disease biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) confirmed on Tuesday that it has completed the acquisition of Alesta Therapeutics, a clinical-stage biot...
BioViva receives US patent for Klotho gene therapy targeting age-related cognitive decline
2 September 2026 - Biotechnology company BioViva USA Inc announced on Tuesday the issuance of US Patent No. 12,564,646, titled 'Treatment of Age-Related Cognitive Decline Using Genetically Modifi...
AstraZeneca completes global licence agreement for Zegfrovy
1 September 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) said on Tuesday it has completed its exclusive global licence agreement with China-based Dizal Pharmaceutic...
AstraZeneca and Daiichi Sankyo's Enhertu plus pertuzumab approved in EU for first-line HER2-positive metastatic breast cancer
1 September 2026 - British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) and Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) on Tuesday announced Europe...